The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins

Journal of Controlled Release

Volumn 52, Issue 1-2, 1998, Pages 1-16

  Bernkop Schnürch, Andreas ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

(Poly)peptide drugs; Complexing agents; Enzyme inhibitors; Peroral administration; Proteolytic enzymes

Indexed keywords

4 AMINOBENZAMIDINE; AMASTATIN; ANTIPAIN; APROTININ; BACITRACIN; CAMOSTAT MESILATE; CHYMOSTATIN; ENZYME INHIBITOR; PEPTIDE HORMONE; PROTEIN; PROTEINASE INHIBITOR;

AMINO ACID ANALYSIS; AMINO ACID SEQUENCE; BRUSH BORDER; DRUG BIOAVAILABILITY; DRUG RELEASE; ENZYME INHIBITION; IN SITU HYBRIDIZATION; PERFUSION; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW;

ADMINISTRATION, ORAL; DIGESTIVE SYSTEM; HUMANS; KINETICS; PEPTIDES; PROTEASE INHIBITORS; PROTEINS;

EID: 0032473473     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(97)00204-6     Document Type: Review

References (102)

1. Zhou X.H. Overcoming enzymatic and absorption barriers to non-parenterally administered protein and peptide drugs. J. Control. Release. 29:1994;239-252.
2. Bernkop-Schnürch A., Fragner R. Investigations into the diffusion behaviour of polypeptides in native intestinal mucus with regard to their peroral administration. Pharm. Sci. 2:1996;361-363.
3. Pusztai A. Transport of proteins through the membranes of the adult gastro-intestinal tract - a potential for drug delivery? Adv. Drug Deliv. Rev. 3:1989;215-228.
4. Bernkop-Schnürch A. Strategien zur peroralen Applikation von Peptid- und proteinwirkstoffen. Sci. Pharm. 65:1997;61-82.
5. Fujii S., Yokoyama T., Ikegaya K., Sato F., Yokoo N. Promoting effect of the new chymotrypsin inhibitor FK-448 on the intestinal absorption of insulin in rats and dogs. J. Pharm. Pharmacol. 37:1985;545-549.
6. Langguth P., Merkle H.P., Amidon G.L. Oral absorption of peptides: the effect of absorption site and enzyme inhibition on the systemic availability of metkephamid. Pharm. Res. 11:1994;528-535.
7. Yamamoto A., Taniguchi T., Rikyuu K., Tsuji T., Fujita T., Murakami M., Muranishi S. Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm. Res. 11:1994;1496-1500.
8. Morishita I., Morishita M., Takayama K., Machida Y., Nagai T. Hypoglycemic effect of novel oral microspheres of insulin with protease inhibitor in normal and diabetic rats. Int. J. Pharm. 78:1992;9-16.
9. Woodley J.F. Enzymatic barriers for GI peptide and protein delivery. Crit. Rev. Ther. Drug. 11:1994;61-95.
10. Woodley J.F. Peptidase activity in the G.I. tract: Distribution between luminal contents and mucosal tissue. Proc. Int. Symp. Control. Release Bioact. Mater. 18:1991;337-338.
11. Ikesue K., Kopeckova P., Kopecek J. Degradation of proteins by guinea pig intestinal enzymes. Int. J. Pharm. 95:1993;171-179.
12. Langguth P., Bohner V., Heizmann J., Merkle H.P., Wolffram S., Amidon G.L., Yamashita S. The challenge of proteolytic enzymes in intestinal peptide delivery. J. Control. Release. 46:1997;39-57.
13. Rinderknecht H., Renner I.G., Douglas A.P., Adham N.F. Profiles of pure pancreatic secretions obtained by direct pancreatic duct cannulation in normal healthy human subjects. Gastroenterology. 75:1978;1083-1089.
14. Rinderknecht H., Fleming R.M. A new, highly sensitive and specific assay for chymotrypsin. Clin. Chim. Acta. 59:1975;139-146.
15. Rick W. Der secretin-pankreozymin-test in der diagnostik der pankreasinsuffizienz. Internist. 11:1970;110-117.
16. Wissenschaftliche Tabellen Geigy, Ciba-Geigy AG, Basel, 1977.
17. Bernkop-Schnürch A., Paikl Ch., Valenta C. Novel bioadhesive chitosan-EDTA conjugate protects leucine enkephalin from degradation by aminopeptidase N. Pharm. Res. 14:1997;917-922.
18. Kolac C., Streichhan P., Lehr C.-M. Oral bioavailability of proteolytic enzymes. Eur. J. Pharm. Biopharm. 42:1996;222-232.
19. Garner C.W., Behal F.J. Human liver aminopeptidase. Role of metal ions in mechanism of action. Biochemistry. 13:1974;3227-3233.
20. Bernkop-Schnürch A., Dundalek K. Novel bioadhesive drug delivery system protecting (poly)peptides from gastric enzymatic degradation. Int. J. Pharm. 138:1996;75-83.
21. Bernkop-Schnürch A., Bratengeyer I., Valenta C. Development of a drug delivery system protecting from trypsinic degradation. Int. J. Pharm. 157:1997;17-25.
22. Takada K., Ushirogawa Y. Effect of pH, dietary proteins and trypsin inhibitors on the hydrolytic rate of human granulocyte colony-stimulating factor (G-CSF) by rat digestive enzymes. J. Pharmacobio-Dyn. 14:1991;363-370.
23. Asada H., Douen T., Mizokoshi Y., Fujita T., Murakami M., Yamamoto A., Muranishi S. Stability of acyl derivatives of insulin in the small intestine: relative importance of insulin association characteristics in aqueous solution. Pharm. Res. 11:1994;1115-1120.
24. Akiyama Y., Lueßen H.L., de Boer A.G., Verhoef J.C., Junginger H.E. Novel peroral dosage forms with protease inhibitory activities. 2. Design of fast dissolving poly(acrylate) and controlled drug-releasing capsule formulations with trypsin inhibiting properties. Int. J. Pharm. 138:1996;13-23.
25. Bernkop-Schnürch A., Marschütz M.K. Development and in vitro evaluation of systems to protect peptide drugs from aminopeptidase N. Pharm. Res. 14:1997;181-185.
26. Yamamoto A., Hayakawa E., Lee V.H.L. Insulin and proinsulin proteolysis in mucosal homogenates of the albino rabbit: Implications in peptide delivery from nonoral routes. Life Sci. 47:1990;2465-2474.
27. Langguth P., Bohner V., Biber J., Merkle H.P. Metabolism and transport of the pentapeptide metkephamid by brush-border membrane vesicles of rat intestine. J. Pharm. Pharmacol. 46:1994;34-40.
28. Heizmann J., Langguth P., Biber A., Oschmann R., Merkle H.P., Wolffram S. Enzymatic cleavage of thymopoietin oligopeptides by pancreatic and intestinal brush-border enzymes. Peptides. 17:1996;1083-1089.
29. Chun H., Sasaki M., Fujiyama Y., Bamba T. Effect of peptide chain length on absorption and intact transport of hydrolyzed soybean peptide in rat intestinal everted sac. J. Clin. Biochem. Nutr. 21:1996;131-140.
30. Friedman D.I., Amidon G.L. Oral absorption of peptides: influence of pH and inhibitors on the intestinal hydrolysis of leu-enkephalin and analogues. Pharm. Res. 8:1991;93-96.
31. Morishita M., Morishita I., Takayama K., Machida Y., Nagai T. Novel oral microspheres of insulin with protease inhibitor protecting from enzymatic degradation. Int. J. Pharm. 78:1992;1-7.
32. Saffran M., Bedra C., Kumar G.S., Neckers D.C. Vasopressin: a model for the study of effects of additives on the oral and rectal administration of peptide drugs. J. Pharm. Sci. 77:1988;33-38.
33. Ushirogawa Y., Nakahigashi Y., Kiriyama A., Takada K. Effect of organic acids, trypsin inhibitors and dietary protein on the pharmacological activity of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats. Int. J. Pharm. 81:1992;133-141.
34. Lehr C.-M., Bouwstra J.A., Kok W., de Boer A.G., Tukker J.J., Verhoef J.C., Breimer D.D., Junginger H.E. Effects of the mucoadhesive polymer polycarbophil on the intestinal absorption of peptide drug in the rat. J. Pharm. Pharmacol. 44:1992;402-407.
35. Geary R.S., Schlameus H.W. Vancomycin and insulin used as models for oral delivery of peptides. J. Control. Release. 23:1993;65-74.
36. New R.R.C., Theakston R.D.G., Zumbuehl O., Iddon D., Friend J. Liposomal immunisation against snake venoms. Toxicon. 21:1985;215-219.
37. Gotoh S., Nakamura R., Nishiyama M., Fujita T., Yamamoto A., Muranishi S. Does Bacitracin have an absorption-enhancing effect in the intestine? Biol. Pharm. Bull. 18:1995;794-796.
38. 2EDTA, and aprotinin on rectal, nasal, and buccal insulin delivery. Pharm. Res. 5:1988;305-308.
39. Lueßen H.L., Rentel C.-O., Kotzé A.F., Lehr C.-M., de Boer A.G., Verhoef J.C., Junginger H.E. Mucoadhesive polymers in peroral peptide drug delivery. IV. Polycarbophil and chitosan are potent enhancers of peptide transport across intestinal mucosae in vitro. J. Control. Release. 45:1997;15-23.
40. Reseland J.E., Holm H., Jacobsen M.B., Jenssen T.G., Hanssen L.E. Proteinase inhibitors induce selective stimulation of human trypsin and chymotrypsin secretion. Hum. Clin. Nutr. 126:1996;634-642.
41. Otsuki M., Ohki A., Okabayashi Y., Suehiro I., Baba S. Effect of synthetic protease inhibitor Camostat on pancreatic exocrine function in rats. Pancreas. 2:1987;164-169.
42. Melmed R.N., El-Aaser A.A., Holt S.J. Hypertrophy and hyperplasia of the neonatal rat exocrine pancreas induced by orally administered soy bean trypsin inhibitor. Biochim. Biophys. Acta. 421:1976;280-288.
43. McGuinness E.E., Hopwood D., Wormsley K.G. Further studies of the effects of raw soya flour on the rat pancreas. Scand. J. Gastroenterol. 17:1982;273-277.
44. Ge Y.C., Morgan R.G.H. The effect of trypsin inhibitor on the pancreas and small intestine of mice. Br. J. Nutr. 70:1993;333-345.
45. Murakawa Y., Kurosaki Y., Nakayama T., Kimura T. Gastrointestinal absorption of recombinant human insulin-like growth factor-I in rats. Proc. Int. Symp. Control. Release Bioact. Mater. 23:1996;589-590.
46. Fjellestadpaulsen A., Dagayabensour L., Hoglund P., Rambaud J.C. Bioavailability of 1-deamino-8-D-arginine vasopressin with an enzyme inhibitor (aprotinin) from the small intestine in healthy volunteers. Eur. J. Clin. Pharmacol. 50:1996;491-495.
47. Kimura T., Sato K., Sugimoto K., Tao R., Murakami T., Kurosaki Y., Nakayama T. Oral administration of insulin as poly(vinyl alcohol)-gel spheres in diabetic rats. Biol. Pharm. Bull. 19:1996;897-900.
48. Trenktrog T., Muller B.W., Specht F.M., Seifert J. Enteric coated insulin pellets - development, drug release and in vivo evaluation. Eur. J. Pharm. Sci. 4:1996;323-329.
49. Birk Y. The Bowman-Birk inhibitor. Int. J. Peptide Protein Res. 25:1985;113-131.
50. Scott M.J., Huckaby C.S., Kato I., Kohr W.J., Laskowski M., Tsai M.-J., O'Malley B.W. Ovoinhibitor introns specify functional domains as in the related and linked ovomucoid gene. J. Biol. Chem. 262:1987;5899-5907.
51. Kanamori T., Mizushima S., Shimizu Y., Morishita H., Kubota H., Nii A., Ogino H., Nagase Y., Kisaragi M., Nobuhara M. Expression and excretion of human pancreatic trypsin inhibitor in lipoprotein-deletion mutant of Escherichia coli. Gene. 66:1988;295-300.
52. 1 esterase. Biochim. Biophys. Acta. 484:1977;417-422.
53. 50 estimation. J. Nat. Prod. 58:1995;823-829.
54. Manjabacas M.C., Valero E., Garciamoreno M., Varon R. Kinetic analysis of an autocatalytic process coupled to a reversible inhibition - the inhibition of the system trypsinogen-trypsin by p-aminobenzamidine. Biol. Chem. Hoppe-Seyler. 376:1995;577-580.
55. L. Stryer, Biochemistry, W.H. Freeman and Company, New York, NY, 1988.
56. Lueßen H.L., Verhoef J.C., Borchard G., Lehr C.-M., de Boer A.G., Junginger H.E. Mucoadhesive polymers in the peroral peptide drug delivery: II. Carbomer and polycarbophil are potent inhibitors of the intestinal proteolytic enzyme trypsin. Pharm. Res. 12:1995;1293-1298.
57. Walker B., McCarthy N., Healy A., Ye T., McKervey M.A. Peptide Glyoxals - a novel class of inhibitor for serine and cysteine proteinases. Biochem. J. 193:1993;321-323.
58. Suenaga H., Mikami M., Yamamoto H., Harada T., Shinkai S. Strong inhibitory effect of sugar biphenylboronic acid complexes on the hydrolytic activity of α-chymotrypsin. J. Chem. Soc. 13:1995;1733-1738.
59. Lueßen H.L., de Leeuw B.J., Pérard D., Lehr C.-M., de Boer A.G., Verhoef J.C., Junginger H.E. Mucoadhesive polymers in peroral peptide drug delivery. I. Influence of mucoadhesive excipients on the proteolytic activity of intestinal enzymes. Eur. J. Pharm. Sci. 4:1996;117-128.
60. Powers J.C., Gupton B.F., Harley A.D., Nishino N., Whitley R.J. Specifity of porcine pancreatic elastase, human leukocyte elastase and cathepsin G. Inhibition with peptide chloromethyl ketones. Biochim. Biophys. Acta. 485:1977;156-166.
61. Bernkop-Schnürch A., Krajicek M.E. Mucoadhesive polymers for peroral peptide delivery: synthesis and evaluation of chitosan-EDTA conjugates. J. Control. Release. 50:1998;215-223.
62. McClellan J.B., Garner C.W. Purification and properties of human intestine alanine aminopeptidase. Biochim. Biophys. Acta. 613:1980;160-167.
63. + spleen T cells. Arch. Biochem. Biophys. 311:1994;174-179.
64. Taki Y., Sakane T., Nadai T., Sezaki H., Amidon G.L., Langguth P., Yamashita S. Gastrointestinal absorption of peptide drug: quantitative evaluation of degradation and the permeation of metkephamid in rat small intestine. J. Pharmacol. Exp. Ther. 274:1995;373-377.
65. Okagava T., Fujita T., Murakami M., Yamamoto A., Shimura T., Tabata S., Kondo S., Muranishi S. Susceptibility of ebiratide to proteolysis in rat intestinal fluid and homogenates and its protection by various protease inhibitors. Life Sci. 55:1994;677-683.
66. Kramer W., Dechent C., Girbig F., Gutjahr U., Neubauer H. Intestinal uptake of dipeptides and β-lactam antibiotics. I. The intestinal uptake system for dipeptides and β-lactam antibiotics is not part of a brush border membrane peptidase. Biochim. Biophys. Acta. 1030:1990;41-49.
67. Inoue T., Kanzaki H., Imai K., Narukawa S., Higuchi T., Katsuragawa H., Maeda M., Mori T. Bestatin, a potent aminopeptidase-N inhibitor, inhibits in vitro decidualization of human endometrial stromal cells. J. Clin. Endocrinol. Metab. 79:1994;171-175.
68. Hussain M.A., Lim M.S.L., Raghavan K.S., Rogers N.J., Hidalgo R., Kettner C.A. A phosphinic acid dipeptide analogue to stabilize peptide drug during their intranasal absorption. Pharm. Res. 9:1992;626-628.
69. Hussain M.A., Shenvi A.B., Rowe S.M., Shefter E. The use of α-aminoboronic acid derivatives to stabilize peptide drugs during their intranasal absorption. Pharm. Res. 6:1989;186-189.
70. Auricchio S., Greco L., de Vizia B., Buonocore V. Dipeptidylaminopeptidase and carboxypeptidase activities of the brush border of rabbit small intestine. Gastroenterology. 75:1978;1073-1079.
71. Giannousis P.P., Bartlett P.A. Phosphorous amino acid analogues as inhibitors of leucine aminopeptidase. J. Med. Chem. 30:1987;1603-1609.
72. Borloo M., de Meester I. Dipeptidyl peptidase IV: development, design, synthesis and biological evaluation of inhibitors. Verh. K. Acad. Geneeskd. Belg. 56:1994;57-88.
73. Kenny A.J., Maroux S. Topology of microvillar membrane hydrolases of kidney and intestine. Physiol. Rev. 62:1982;91-128.
74. Smith T.K., Ikeda Y., Fujii J., Taniguchi N., Meister A. Different sites of acivicin binding and inactivation of γ-glutamyl transpeptidases. Proc. Natl. Acad. Sci. USA. 92:1995;2360-2364.
75. Diaz-Flores M., Duran-Reyes G., Hicks J.J. Arrest of rat embryonic development by the inhibition of γ-glutamyl transpeptidase. I. Intrauterine administration of L-serine-borate complex. Int. J. Fertil. Menop. Stud. 39:1994;234-238.
76. McGwire G.B., Skidgel R.A. Extracellular conversion of epidermal growth factor (EGF) to des-Arg(53)-EGF by carboxypeptidase M. J. Biol. Chem. 270:1995;17154-17158.
77. Bunnett N.W., Turner A.J., Hryszko J., Kobayashi R., Walsh J.H. Isolation of endopeptidase-24.11 (EC 3.4.24.11, 'Enkephalinase') from the pig stomach. Gastroenterology. 95:1988;952-957.
78. 1] Peptide T amide: implication for oral drug delivery. Biochim. Biophys. Acta. 1245:1995;62-68.
79. Ishida H., Scicli A.G., Carretero O.A. Role of angiotensin converting enzyme and other peptidases in in vivo metabolism of kinins. Hypertension (Dallas). 14:1989;322-327.
80. Seymour A.A., Sheldon J.H., Smith P.L., Asaad M., Rogers W.L. Potentiation of the renal responses to bradykinin by inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in anestetized dogs. J. Pharmacol. Exp. Ther. 269:1994;263-269.
81. Hickey R.J. Bacitracin, its manufacture an uses. Prog. Ind. Microbiol. 5:1964;93-150.
82. Raehs S.C., Sandow J., Wirth K., Merkle H.P. The adjuvant effect of bacitracin on nasal absorption of gonadorelin and burerelin in rats. Pharm. Res. 5:1988;689-693.
83. Drapeau G., Petitclerc E., Toulouse A., Marceau F. Dissociation of the antimicrobial activity of bacitracin USP from its renovascular effects. Antimicrob. Agents Chemother. 36:1992;955-961.
84. McConnell R.M., Frizzell D., Evans A.C.A., Jones W., Cagle C. New pepstatin analogues: synthesis and pepsin inhibition. J. Med. Chem. 34:1991;2298-2300.
85. Itoh M., Matsuo Y. Gastric ulcer treatment with intravenous human epidermal growth factor: A double-blind controlled clinical study. J. Gastroenterol. Hepatol. 9:1994;S78-S83.
86. Plumpton C., Kalinka S., Martin R.C., Horton J.K., Davenport A.P. Effects of phosphoramidon and pepstatin A on the secretion of endothelin-1 and big endothelin-1 by human umbilical vein endothelial cells - measurement by two-site enzyme-linked immunosorbent assays. Clin. Sci. 87:1994;245-251.
87. McCaffrey G., Jamieson J.C. Evidence for the role of a cathepsin D-like activity in the release of gal β1-4 glcnac α2-6 sialyltransferase from rat and mouse liver in whole-cell systems. Comp. Biochem. Phys. C. 104:1993;91-94.
88. Carmel R. In vitro studies of gastric juice in patients with food-cobalamin malabsorption. Digest. Dis. Sci. 39:1994;2516-2522.
89. Lindahl A., Ungell A.-L., Knutson L., Lennernäs H. Characterization of fluids from the stomach and proximal jejunum in men and women. Pharm. Res. 14:1997;497-502.
90. Sanderink G.-J., Artur Y., Siest G. Human aminopeptidases: a review of the literature. J. Clin. Chem. Clin. Biochem. 26:1988;795-807.
91. + efflux in vitro. J. Biol. Chem. 269:1994;10088-10092.
92. Mizuma T., Koyanagi A., Awazu S. Intestinal transport and metabolism of analgetic dipeptide, Kyotorphin - rate-limiting factor in intestinal absorption of peptide as drug. Biochim. Biophys. Acta. 1335:1997;111-119.
93. Lee V.H.L. Protease inhibitors and penetration enhancers as approaches to modify peptide absorption. J. Control. Release. 13:1990;213-223.
94. Bernkop-Schnürch A., Göckel N.C. Development and analysis of a polymer protecting from luminal enzymatic degradation caused by α-chymotrypsin. Drug Dev. Ind. Pharm. 23:1997;733-740.
95. Lehr C.-M. Bioadhesion technologies for the delivery of peptide and protein drugs to the gastrointestinal tract. Crit. Rev. Ther. Drug Carrier Syst. 11:1994;119-160.
96. Junginger H.E. Bioadhesive polymer systems for peptide delivery. Acta Pharm. Technol. 36:1990;110-126.
97. Lueßen H.L., de Leeuw B.J., Langemeyer M.W., de Boer A.G., Verhoef J.C., Junginger H.E. Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Pharm. Res. 13:1996;1668-1672.
98. Brochard G., Lueßen H.L., Verhoef J.C., Lehr C.-M., de Boer A.G., Junginger H.E. The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption III: Effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro. J. Control. Release. 39:1996;131-138.
99. Lueßen H.L., Bohner V., Pérard D., Langguth P., Verhoef J.C., de Boer A.G., Merkle H.P., Junginger H.E. Mucoadhesive polymers in peroral peptide drug delivery. V. Effect of poly(acrylates) on the enzymatic degradation of peptide drugs by intestinal brush border membrane vesicles. Int. J. Pharm. 141:1996;39-52.
100. Bernkop-Schnürch A., Apprich I. Synthesis and evaluation of a modified mucoadhesive polymer protecting from α-chymotrypsinic degradation. Int. J. Pharm. 146:1997;247-254.
101. Bernkop-Schnürch A., Schwarz G., Kratzel M. Modified mucoadhesive polymers for the peroral administration of mainly elastase degradable therapeutic (poly)peptides. J. Control. Release. 47:1997;113-121.
102. Bernkop-Schnürch, A., Scerbe-Saiko, A., Synthesis and in vitro evaluationof chitosan-EDTA-protease-inhibitor conjugates which might be useful in oral delivery of peptides and proteins, Pharm. Res. 14 (1997) (in press).